InsiderTrades.com logo
M Milne Jr net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

M Jr Biography and Net Worth

Director of Amylyx Pharmaceuticals

Dr. Milne began serving as a director of Amylyx in 2015. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. George M. Milne, Jr., Ph.D. became a Radius Venture Partner in 2002. Milne has served on the Board of Directors at many different companies and organizations including currently Charles River Laboratories, Mettler-Toledo, Inc., BioStorage Technologies Inc., Draper Laboratory, the Sea Research Foundation, and the New York Botanical Garden. During his notable career, Milne has received a variety of honors, including an award from Yale University for lifetime contributions to commerce, innovation or education, the Connecticut College medal, and the distinguished citizen award from Big Brothers/Big Sisters. Dr. Milne received a B.S. in Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.

What is M Milne Jr's net worth?

The estimated net worth of M Milne Jr is at least $12.44 million as of September 3rd, 2024. Jr owns 858,571 shares of Amylyx Pharmaceuticals stock worth more than $12,440,694 as of December 4th. This net worth approximation does not reflect any other assets that Jr may own. Learn More about M Milne Jr's net worth.

How do I contact M Milne Jr?

The corporate mailing address for Jr and other Amylyx Pharmaceuticals executives is , , . Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on M Milne Jr's contact information.

Has M Milne Jr been buying or selling shares of Amylyx Pharmaceuticals?

M Milne Jr has not been actively trading shares of Amylyx Pharmaceuticals within the last three months. Most recently, on Tuesday, September 3rd, George M. Milne, Jr. bought 100,000 shares of Amylyx Pharmaceuticals stock. The stock was acquired at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the transaction, the director now directly owns 858,571 shares of the company's stock, valued at $1,888,856.20. Learn More on M Milne Jr's trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 12/1/2025.

M Milne Jr Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/3/2024Buy100,000$2.20$220,000.00858,571View SEC Filing Icon  
3/16/2023Sell35,000$31.89$1,116,150.00862,021View SEC Filing Icon  
See Full Table

M Milne Jr Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows George M Milne Jr's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.49
Low: $13.91
High: $14.64

50 Day Range

MA: $14.00
Low: $12.18
High: $15.79

2 Week Range

Now: $14.49
Low: $2.60
High: $16.96

Volume

781,740 shs

Average Volume

1,403,731 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A